20th Sep 2013 12:43
LONDON (Alliance News) - European approval for Plethora Solutions Holdings PLC's premature ejaculation treatment moved a step closer Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended its approval by the European Commission.
The spray treatment, known as PSD502 or Lidocaine Prilocaine Plethora, is for primary premature ejaculation in adult men.
"Today's announcement by the CHMP is the key opinion the Company has been seeking to obtain European approval. We are delighted by today's news after such a significant period to reach this milestone," Plethora Chief Executive Ronald Openshaw said in a statement. "Our efforts are now focussed on achieving a European launch post EC approval and on the US filing with the FDA."
The company said it will start selling the product in Europe as soon as possible after the European Commission gives the approval it now expects.
Plethora shares were up 57% at 12.56 pence, the biggest increase on the AIM market.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Plethora Solutions Holdings Plc